RAS突变-话题@MedSci

#RAS突变#

56篇内容 | 1012人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1585338, encodeId=dbf01585338ed, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌, objectType=article, longId=728247, objectId=5740e2824790, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5740e2824790, replyNumber=0, likeNumber=45, createdTime=2022-06-01, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5740e2824790, moduleTitle=ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5740e2824790)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585337, encodeId=5691158533ed2, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=Clin Cancer Res：比美替尼联合瑞博西林治疗NRAS突变的黑色素瘤, objectType=article, longId=301035, objectId=dece30103500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dece30103500, replyNumber=0, likeNumber=45, createdTime=2022-03-19, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dece30103500, moduleTitle=Clin Cancer Res：比美替尼联合瑞博西林治疗NRAS突变的黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dece30103500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585336, encodeId=b990158533615, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, objectType=article, longId=300803, objectId=cb143008036b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb143008036b, replyNumber=0, likeNumber=23, createdTime=2022-03-16, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb143008036b, moduleTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb143008036b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585335, encodeId=5798158533557, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), objectType=article, longId=291939, objectId=aea92919392a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aea92919392a, replyNumber=0, likeNumber=0, createdTime=2021-12-17, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aea92919392a, moduleTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aea92919392a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585334, encodeId=ba96158533485, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析, objectType=article, longId=218842, objectId=20e9218842d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e9218842d0, replyNumber=0, likeNumber=51, createdTime=2021-10-20, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e9218842d0, moduleTitle=Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20e9218842d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585333, encodeId=4c291585333f4, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), objectType=article, longId=217348, objectId=9f0d21e348f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f0d21e348f1, replyNumber=0, likeNumber=24, createdTime=2021-09-21, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f0d21e348f1, moduleTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f0d21e348f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585332, encodeId=63df15853322a, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益, objectType=article, longId=206081, objectId=4595206081b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4595206081b2, replyNumber=0, likeNumber=33, createdTime=2021-01-24, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4595206081b2, moduleTitle=复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4595206081b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585331, encodeId=493c1585331fd, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=Br J Cancer：RAS突变对于早发性和晚发性结直肠癌肝转移切除患者总体生存期的影响, objectType=article, longId=203813, objectId=1a49203813ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a49203813ee, replyNumber=0, likeNumber=45, createdTime=2020-11-28, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a49203813ee, moduleTitle=Br J Cancer：RAS突变对于早发性和晚发性结直肠癌肝转移切除患者总体生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a49203813ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585330, encodeId=2f3a158533018, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=Blood：靶向GCK通路 | 治疗RAS突变型MM的一种新选择性, objectType=article, longId=202004, objectId=1ba920200434, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ba920200434, replyNumber=0, likeNumber=43, createdTime=2020-10-13, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ba920200434, moduleTitle=Blood：靶向GCK通路 | 治疗RAS突变型MM的一种新选择性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ba920200434)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585329, encodeId=1f541585329d9, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=NEJM：Sotorasib治疗KRAS突变晚期实体瘤效果显著, objectType=article, longId=201173, objectId=98dc2011e3ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98dc2011e3ba, replyNumber=0, likeNumber=45, createdTime=2020-09-26, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98dc2011e3ba, moduleTitle=NEJM：Sotorasib治疗KRAS突变晚期实体瘤效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98dc2011e3ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585328, encodeId=8c591585328c4, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=Br J Cancer：新一代抗体-药物偶联物有望治疗KRAS突变型胰腺癌, objectType=article, longId=200728, objectId=dc7f200e286c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc7f200e286c, replyNumber=0, likeNumber=37, createdTime=2020-09-17, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc7f200e286c, moduleTitle=Br J Cancer：新一代抗体-药物偶联物有望治疗KRAS突变型胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc7f200e286c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585327, encodeId=91aa158532ef4, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=NAT COMMUN：针对铜代谢杀死KRAS突变肿瘤, objectType=article, longId=198345, objectId=14b81983450d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b81983450d, replyNumber=0, likeNumber=34, createdTime=2020-07-31, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b81983450d, moduleTitle=NAT COMMUN：针对铜代谢杀死KRAS突变肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14b81983450d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585326, encodeId=b1661585326f4, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=PNAS：中山大学高国全团队发现，二甲双胍对KRAS突变型结直肠癌有效, objectType=article, longId=194988, objectId=4bc3194988c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bc3194988c4, replyNumber=0, likeNumber=38, createdTime=2020-06-01, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bc3194988c4, moduleTitle=PNAS：中山大学高国全团队发现，二甲双胍对KRAS突变型结直肠癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bc3194988c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585325, encodeId=79b215853257e, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=AACR 2020：KRAS突变在不同癌肿的发生率, objectType=article, longId=193176, objectId=cdb61931e68c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdb61931e68c, replyNumber=0, likeNumber=41, createdTime=2020-05-01, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdb61931e68c, moduleTitle=AACR 2020：KRAS突变在不同癌肿的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdb61931e68c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585324, encodeId=8e9f1585324b9, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=CELL REP：研究人员发现针对癌症KRAS突变的新疗法, objectType=article, longId=191876, objectId=d4601918e6f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4601918e6f6, replyNumber=0, likeNumber=34, createdTime=2020-04-11, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4601918e6f6, moduleTitle=CELL REP：研究人员发现针对癌症KRAS突变的新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4601918e6f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585323, encodeId=a4591585323ee, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=KRAS突变靶向药物AMG510即将进入中国开展临床试验, objectType=article, longId=191150, objectId=311c19115003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=311c19115003, replyNumber=0, likeNumber=40, createdTime=2020-04-01, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=311c19115003, moduleTitle=KRAS突变靶向药物AMG510即将进入中国开展临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=311c19115003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, objectType=article, longId=186925, objectId=3f7618692587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f7618692587, replyNumber=0, likeNumber=47, createdTime=2020-01-30, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f7618692587, moduleTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f7618692587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585321, encodeId=8e90158532153, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=Modern Pathology：反极性乳头状肾细胞癌中鉴定了复发性KRAS突变, objectType=article, longId=186807, objectId=d11a18680eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d11a18680eac, replyNumber=0, likeNumber=33, createdTime=2020-01-29, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d11a18680eac, moduleTitle=Modern Pathology：反极性乳头状肾细胞癌中鉴定了复发性KRAS突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d11a18680eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585320, encodeId=47a3158532058, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=贝伐珠单抗联合FOLFOX，提高RAS突变型肠癌肝转移切除率, objectType=article, longId=181068, objectId=1eae18106814, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eae18106814, replyNumber=0, likeNumber=46, createdTime=2019-10-15, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eae18106814, moduleTitle=贝伐珠单抗联合FOLFOX，提高RAS突变型肠癌肝转移切除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1eae18106814)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1585319, encodeId=823b158531943, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, objectTitle=Clinica Chimica Acta：利用改进的野生型阻断剂可在单管中敏感、选择性地检测密码子12和13 KRAS突变, objectType=article, longId=179432, objectId=0a3e1e94321f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a3e1e94321f, replyNumber=0, likeNumber=31, createdTime=2019-09-15, rootId=0, userName=bioon7, userId=6f2c17156536, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a3e1e94321f, moduleTitle=Clinica Chimica Acta：利用改进的野生型阻断剂可在单管中敏感、选择性地检测密码子12和13 KRAS突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a3e1e94321f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

RAS突变

2020-05-29

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

ASCO：Sintilimab联合CapeOx和贝伐单抗一线治疗RAS突变+转移性结直肠癌

2022-06-01

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

Clin Cancer Res：比美替尼联合瑞博西林治疗NRAS突变的黑色素瘤

2022-03-19

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效

2022-03-16

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C)

2021-12-17

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析

2021-10-20

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C)

2021-09-21

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

复发低级别浆液性卵巢癌：KRAS突变可预测MEK抑制剂Binimetinib获益

2021-01-24

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

Br J Cancer：RAS突变对于早发性和晚发性结直肠癌肝转移切除患者总体生存期的影响

2020-11-28

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

Blood：靶向GCK通路 | 治疗RAS突变型MM的一种新选择性

2020-10-13

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

NEJM：Sotorasib治疗KRAS突变晚期实体瘤效果显著

2020-09-26

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

Br J Cancer：新一代抗体-药物偶联物有望治疗KRAS突变型胰腺癌

2020-09-17

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

NAT COMMUN：针对铜代谢杀死KRAS突变肿瘤

2020-07-31

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

PNAS：中山大学高国全团队发现，二甲双胍对KRAS突变型结直肠癌有效

2020-06-01

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

AACR 2020：KRAS突变在不同癌肿的发生率

2020-05-01

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

CELL REP：研究人员发现针对癌症KRAS突变的新疗法

2020-04-11

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

KRAS突变靶向药物AMG510即将进入中国开展临床试验

2020-04-01

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益

2020-01-30

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

Modern Pathology：反极性乳头状肾细胞癌中鉴定了复发性KRAS突变

2020-01-29

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

贝伐珠单抗联合FOLFOX，提高RAS突变型肠癌肝转移切除率

2019-10-15

bioon7 (审核中...)

前往app查看评论内容

#RAS突变#

Clinica Chimica Acta：利用改进的野生型阻断剂可在单管中敏感、选择性地检测密码子12和13 KRAS突变

2019-09-15

科室
- - 订阅+
  - 更多科室
工具
服务